PLx Pharma (PLXP) Now Covered by Janney Montgomery Scott

Equities research analysts at Janney Montgomery Scott started coverage on shares of PLx Pharma (NASDAQ:PLXP) in a research note issued on Friday, MarketBeat.com reports. The firm set a “buy” rating and a $14.00 price target on the biotechnology company’s stock. Janney Montgomery Scott’s target price would suggest a potential upside of 112.12% from the stock’s current price.

Several other research firms also recently issued reports on PLXP. ValuEngine upgraded shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a report on Monday, December 4th. Zacks Investment Research downgraded shares of PLx Pharma from a “buy” rating to a “sell” rating in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $11.08.

PLx Pharma (NASDAQ:PLXP) traded up $0.50 during trading on Friday, reaching $6.60. 114,870 shares of the company’s stock were exchanged, compared to its average volume of 9,503. The company has a debt-to-equity ratio of 0.56, a current ratio of 8.99 and a quick ratio of 8.88. PLx Pharma has a 52-week low of $5.60 and a 52-week high of $12.80.

PLx Pharma (NASDAQ:PLXP) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.03). equities analysts forecast that PLx Pharma will post -1.71 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in PLx Pharma stock. Susquehanna International Group LLP acquired a new position in shares of PLx Pharma Inc (NASDAQ:PLXP) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 229,800 shares of the biotechnology company’s stock, valued at approximately $1,413,000. Susquehanna International Group LLP owned 5.24% of PLx Pharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 21.87% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/20/plx-pharma-plxp-now-covered-by-janney-montgomery-scott.html.

PLx Pharma Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply